title: Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
abstract: New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias. Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified. These variants are expressed in chronic myelogenous leukemia and acute lymphocytic leukemia patients. The transcriptional products were characterized at their C-terminus by a large amino acid portion derived from out of frame (OOF) reading of the ABL gene. This OOF peptide is expressed only in leukemic cells and has no homology with known human proteins. In order to study an in vivo model, three 39-amino acid peptides, each corresponding to a third of the whole human OOF peptide sequence, were tested for their capacity to elicit specific immune responses in HLA A2.1 transgenic mice. Peptides A and B, but not C, induced the production of specific antisera, while A and C induced the generation of specific cytotoxic T lymphocytes.
authors.affiliation: Department of Pharmacology, School of Medicine, University of Milan, Milan, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Casnici
authors.forename: G
authors.initials: G
authors.lastname: Volpe
authors.forename: D
authors.initials: D
authors.lastname: Lattuada
authors.forename: K
authors.initials: K
authors.lastname: Crotta
authors.forename: M
authors.initials: M
authors.lastname: Kuka
authors.forename: C
authors.initials: C
authors.lastname: Panuzzo
authors.forename: C
authors.initials: C
authors.lastname: Mastrotto
authors.forename: G
authors.initials: G
authors.lastname: Tonon
authors.forename: V M
authors.initials: VM
authors.lastname: Fazio
authors.forename: G
authors.initials: G
authors.lastname: Saglio
authors.forename: O
authors.initials: O
authors.lastname: Marelli
mesh_terms: D017398:Alternative Splicing; D000595:Amino Acid Sequence; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D016368:Frameshift Mutation / Q000235:genetics / Q000276:immunology*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000235:genetics; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D010455:Peptides / Q000235:genetics / Q000276:immunology; D051562:Proto-Oncogene Proteins c-bcr / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015789:HLA-A2 Antigen; D010455:Peptides; D007371:Interferon-gamma; D016044:Fusion Proteins, bcr-abl; D051562:Proto-Oncogene Proteins c-bcr